Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Cancer Discov. 2016 Apr 5;6(6):594–600. doi: 10.1158/2159-8290.CD-15-1192

Figure 2.

Figure 2

Serial imaging demonstrating progression on temozolomide followed by rapid and durable response to dabrafenib and trametinib in a patient with a refractory BRAF mutant rectal neuroendocrine tumor (panel A). Parallel decrease in serum chromogranin A and quantitative urine BRAF ctDNA detection are shown in panels B and C respectively.